Clinical trial
Study Of Denagliptin In Subjects With Type 2 Diabetes Mellitus (T2DM)
NCT00387972 · GlaxoSmithKline, Industry · Withdrawn
Key facts
| NCT number | NCT00387972 |
|---|---|
| Title | Study Of Denagliptin In Subjects With Type 2 Diabetes Mellitus (T2DM) |
| Official title | A Multi-center, Double-blind, Parallel-group, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Denagliptin in Subjects With Type 2 Diabetes Mellitus |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Withdrawn |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | denagliptin (GW823093) |
| Enrollment | 0 |
| Start date | May 1, 2006 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Oct 13, 2006 |
| Last update posted | Apr 17, 2015 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: